NT113, a Pan-Erbb Inhibitor With High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts With EGFR Amplification

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-14-0306
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

High Level EGFR Amplification in a Newly Established Glioblastoma Cell Line 170-Mg-Ba

Neoplasma
Cancer Research
2019English

Mesenchymal Stromal Cells Loaded With Paclitaxel Induce Cytotoxic Damage in Glioblastoma Brain Xenografts

Stem Cell Research and Therapy
GeneticsCell BiologyMolecular BiologyBiochemistryMedicineMolecular Medicine
2015English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

The Influence of the Combined Treatment With Vadimezan (ASA404) and Taxol on the Growth of U251 Glioblastoma Xenografts

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

A Small-Molecule Oligosaccharyltransferase Inhibitor With Pan-Flaviviral Activity

Cell Reports
BiochemistryGeneticsMolecular Biology
2017English

A Brain-Penetrant MET Inhibitor Achieves Responses in Glioblastoma

Cancer Discovery
Oncology
2018English

PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations

Scientific Reports
Multidisciplinary
2019English

EGFR Cooperates With EGFRvIII to Recruit Macrophages in Glioblastoma

Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy